Trial reportmAbs2014
First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers.
Trial report in mAbs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- Comparison between a chimeric anti-methamphetamine monoclonal antibody and humanized antibodies on pharmacological effects of methamphetamine.Psychopharmacology · 2026Article
- An antifentanyl monoclonal antibody reverses fentanyl-induced apnea in pigs.The Journal of pharmacology and experimental therapeutics · 2025Article
- Novel therapeutics in development for the treatment of stimulant-use disorder.Current opinion in neurobiology · 2024Review
- Investigation of monoclonal antibody CSX-1004 for fentanyl overdose.Nature communications · 2023Article
- Article
- Immunotherapeutic strategies for treating opioid use disorder and overdose.Expert opinion on investigational drugs · 2023Review
- Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development.Human vaccines & immunotherapeutics · 2022Article
- Vaccines against Drug Abuse-Are We There Yet?Vaccines · 2022Review
- Pharmacological Profiling of Antifentanyl Monoclonal Antibodies in Combination with Naloxone in Pre- and Postexposure Models of Fentanyl Toxicity.The Journal of pharmacology and experimental therapeutics · 2022Article
- Neuroscientific Basis of Treatment for Substance Use Disorders.Noro psikiyatri arsivi · 2022Review
- In Vitro and In Vivo Sequestration of Methamphetamine by a Sulfated Acyclic CB[n]-Type Receptor.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- In Vitro and In Vivo Sequestration of Phencyclidine by MeChemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- Current and Emerging Treatments for Methamphetamine Use Disorder.Current neuropharmacology · 2021Review
- Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats.The Journal of pharmacology and experimental therapeutics · 2020Article
- Antibody production and pharmacokinetics of METH in rats following vaccination with the METH vaccine, IXT-v100, adjuvanted with GLA-SE.Drug and alcohol dependence · 2019Article
- Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists.Psychopharmacology · 2019Review
- Monoclonal Antibodies for Combating Synthetic Opioid Intoxication.Journal of the American Chemical Society · 2019Article
- Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2019Article
- Ethical Implications in Vaccine Pharmacotherapy for Treatment and Prevention of Drug of Abuse Dependence.Journal of bioethical inquiry · 2018Article
- Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
This first-in-human study examined the safety and pharmacokinetics of ch-mAb7F9, an anti-methamphetamine monoclonal antibody, in healthy volunteers. Single, escalating doses of ch-mAb7F9 over the range of 0.2 to 20 mg/kg were administered to 42 subjects who were followed for 147 d. Safety was measured by physical examinations, adverse events, vital signs, electrocardiograms, and clinical laboratory testing. Serum ch-mAb7F9 concentration and immunogenicity analyses were performed. There were no serious adverse reactions or discontinuations from the study due to adverse events. No trends emerged in the frequency, relatedness, or severity of adverse events with increased dose or between active and placebo treated subjects. Ch-mAb7F9 displayed expected IgG pharmacokinetic parameters, including a half-life of 17-19 d in the 3 highest dose groups and volume of distribution of 5-6 L, suggesting the antibody is confined primarily to the vascular compartment. Four (12.5%) of the 32 subjects receiving ch-mAb7F9 were confirmed to have developed a human anti-chimeric antibody response by the end of the study; however, this response did not appear to be dose related. Overall, no apparent safety or tolerability concerns were identified; a maximum tolerated dose was not reached in this Phase 1 study. Ch-mAb7F9 therefore appears safe for human administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.